Silence Therapeutics Ratios (2019-2025) | SLN

Ratios Jun2019 Dec2019 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Profitability
Gross Margin -17.25%31.34%51.11%32.43%0.00%40.19%60.24%35.44%28.98%19.01%60.14%68.90%42.57%35.87%82.16%-322.13%-142.92%91.95%61.97%62.05%59.75%
EBT Margin -479,879.28%-240.55%-313,931.30%-470.49%0.00%-328.85%-167.28%-368.38%-276.65%-315.84%-111.42%-131.92%-381.02%-713.01%-13.17%-2,440.88%-2,369.49%49.90%-20,091.55%-12,207.14%-13,180.50%
EBIT Margin -481.29%-654.64%-297.11%-478.60%0.00%-329.91%-173.40%-386.74%-404.06%-230.03%-106.81%-125.85%-453.86%-633.59%-33.58%-2,890.96%-1,954.76%-17.20%-20,006.34%-10,697.77%-16,505.66%
EBITDA Margin -481.29%-654.64%-297.11%-478.60%0.00%-329.91%-173.40%-386.74%-404.06%-230.03%-106.81%-125.85%-453.86%-633.59%-33.58%-2,890.96%-1,954.76%-17.20%-20,006.34%-10,697.77%-16,505.66%
Operating Margin -481.29%-654.64%-297.11%-478.60%0.00%-329.91%-173.40%-386.74%-404.06%-230.03%-106.81%-125.85%-453.86%-633.59%-35.55%-2,890.96%-2,002.47%-17.20%-20,006.34%-10,697.77%-16,505.66%
Net Margin -479,879.28%-240.55%-313,931.30%-470.49%0.00%-328.85%-167.28%-368.38%-276.65%-315.84%-111.42%-131.92%-381.02%-713.01%-27.19%-2,751.80%-2,615.77%48.61%-20,091.55%-12,211.61%-13,181.13%
FCF Margin 1,156.94%-16.95%-384,192.11%980.01%0.00%-125.95%-250.31%-225.94%-277.57%-287.20%-67.07%-164.31%-173.41%-865.46%-60.56%-759.54%-1,700.63%-108.84%-8,671.13%-9,749.55%-6,857.23%
Efficiency
Assets Average 48.93M91.76M254.31M262.38M328.68M369.03M424.24M495.55M492.86M497.46M491.90M476.01M537.14M664.14M773.19M511.92M193.97M175.27M156.01M
Equity Average 30.91M30.59M27.82M17.02M8.42M23.03M17.75M20.33M23.25M88.96M149.39M134.35M130.36M123.38M103.45M84.11M
Invested Capital 34.94M26.88M34.30M11.96M33.08M22.55M11.49M5.35M25.89M20.17M15.34M25.33M21.16M157.17M142.01M122.80M134.02M112.74M94.16M74.06M
Asset Utilization Ratio 0.02M0.02M0.01M0.01M0.050.040.060.070.070.070.060.030.030.080.140.160.17
Leverage & Solvency
Equity Ratio 0.900.450.280.110.230.090.050.210.180.130.200.180.640.600.580.660.610.570.50
Valuation
Enterprise Value -14.81M-17.38M-12.82M-17.96M-38.22M-63.05M-99.57M-98.53M-99.13M-79.56M-64.94M-106.09M-64.30M-56.80M-37.19M-74.50M-67.06M-143.41M-138.19M-80.50M-147.33M-208.15M-186.62M-122.36M
Return Ratios
Return on Sales -4,798.79%-2.41%-3,139.31%-4.70%0.00%-3.29%-1.67%-3.68%-2.77%-3.16%-1.11%-1.32%-3.81%-7.13%-0.27%-27.52%-26.16%0.49%-200.92%-122.12%-131.81%
Return on Capital Employed -0.29%-0.21%-0.18%-0.16%-0.14%-0.13%-0.12%-0.11%-0.11%-0.12%-0.09%-0.09%-0.09%-0.13%-0.49%-0.54%-0.60%
Return on Invested Capital -0.49%-0.70%-0.84%-0.99%
Return on Assets -0.26%-0.24%-0.19%-0.17%-0.13%-0.12%-0.12%-0.12%-0.13%-0.13%-0.10%-0.09%-0.11%-0.10%-0.40%-0.47%-0.41%
Return on Equity -2.35%-3.71%-7.40%-2.65%-3.33%-3.03%-2.69%-0.58%-0.39%-0.63%-0.41%-0.63%-0.80%-0.77%